Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alejandro Lazo-Langner

Showing results (131-140 of 135) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 135 results.
Journal of Thrombosis and Haemostasis : JTH|August 6, 2025
Racial Disparities in the Incidence and Risk Factors for Major Bleeding during Extended Anticoagulant Therapy for Venous ThromboembolismDuale Omar, Michael J Kovacs, Alejandro Lazo-Langner, et al.
Blood Advances|April 19, 2022
Rivaroxaban for the treatment of noncirrhotic splanchnic vein thrombosis: an interventional prospective cohort studyWalter Ageno, Jan Beyer Westendorf, Laura Contino, et al.
The New England Journal of Medicine|December 5, 2018
Apixaban to Prevent Venous Thromboembolism in Patients with CancerMarc Carrier, Karim Abou-Nassar, Ranjeeta Mallick, et al.
European Journal of Haematology|June 10, 2019
Implementation of an NGS-based sequencing and gene fusion panel for clinical screening of patients with suspected hematologic malignanciesMichael A Levy, Stephanie Santos, Jennifer Kerkhof, et al.
The New England Journal of Medicine|March 11, 2026
Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous ThromboembolismLana A Castellucci, Vivien M Chen, Michael J Kovacs, et al.
Pageof 14

Showing results (131-140 of 135) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 135 results.
Journal of Thrombosis and Haemostasis : JTH|August 6, 2025
Racial Disparities in the Incidence and Risk Factors for Major Bleeding during Extended Anticoagulant Therapy for Venous ThromboembolismDuale Omar, Michael J Kovacs, Alejandro Lazo-Langner, et al.
Blood Advances|April 19, 2022
Rivaroxaban for the treatment of noncirrhotic splanchnic vein thrombosis: an interventional prospective cohort studyWalter Ageno, Jan Beyer Westendorf, Laura Contino, et al.
The New England Journal of Medicine|December 5, 2018
Apixaban to Prevent Venous Thromboembolism in Patients with CancerMarc Carrier, Karim Abou-Nassar, Ranjeeta Mallick, et al.
European Journal of Haematology|June 10, 2019
Implementation of an NGS-based sequencing and gene fusion panel for clinical screening of patients with suspected hematologic malignanciesMichael A Levy, Stephanie Santos, Jennifer Kerkhof, et al.
The New England Journal of Medicine|March 11, 2026
Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous ThromboembolismLana A Castellucci, Vivien M Chen, Michael J Kovacs, et al.
Pageof 14